الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
Objective: This study aimed to compare the efficiency of sacubitril/valsartan combination compared to valsartan in the treatment of heart failure (HF) patients in Egypt over six months and how this is reflected on the ejection fraction (EF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
Methods: a prospective randomized, active-controlled trial. sixty heart failure patients with reduced ejection fraction (HFrEF) received either sacubitril/valsartan combination or valsartan with an allocation of a 1:1 for six months with the determination of baseline and exit EF and NT-proBNP levels in both groups.
Key Findings: After 6 months of pharmacotherapy, a significant increase was observed in the EF level of HF patients receiving sacubitril/valsartan, compared to those receiving valsartan. At baseline, the mean of EF level of patients receiving sacubitril/valsartan was 33.18±5.9 %, while at the end, it was 38.68 ±5.29 % (p<0. 05). Also, there was a significant decrease in the NT-proBNP level in the sacubitril/valsartan group from 547.14±101.21 pg/ml at baseline to 150±26.39 pg/ml (p<0.05) at the end. Finally, there was an advancement in the health-related quality of life for patients received sacubitril/valsartan demonstrated by significant improvement of New York Heart Association Functional Classification (NYHA) class (p<0.05) and reduction in the frequency of hospitalization and total hospitalization days (p<0.05).
Conclusion: Sacubitril/valsartan represents an essential advancement in the treatment of HF, as it lowers the mean value of NT-proBNP level, raises EF level, and improves the quality of life in HF patients.